Sign in
Taking peopleNo phase

Blood clots in relatives of women with hormone-related venous thromboembolism

Compares past blood clots in close relatives of women with and without clots.

Key facts

Who runs it
University Hospital, Brest
Where
France8 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure
Status
Recruiting
People taking part
2,640 people, planned
Started
24 Oct 2017
Planned end
24 Oct 2026
Type of study
Observational, 2 groups
Treatments tested
  • Case group
  • Control group
Record updated
16 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for close blood relatives (parents, brothers, sisters, children) of women aged 18 to 50. Some of these women had a first blood clot in a vein while taking estrogen-containing pills or while pregnant. The others had the same hormone exposure but never had a clot.

Age
16 years and older
Sex
All sexes
Disease stage
The woman in the family (aged 18-50) had a first clot in a deep vein of the leg or in the lung while on hormones. Scans must have confirmed it. Or she is a control woman with the same hormone exposure and no clot ever.
Earlier treatment
Relatives cannot join if the woman in their family took medicine to prevent clots during her pregnancy or while using contraception.

Main reasons for not taking part

  • Relatives who had a clot only in a surface vein or a muscle vein
  • Relatives under 16 years of age
  • Vulnerable adults under guardianship or curatorship
  • No information can be obtained about the relatives
  • No health insurance

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • First-degree relatives (biological parents, brothers, sisters, children) of women of childbearing age 18-50 years (propositus) with a first MVTE in the hormonal setting and matched control women in the same hormonal setting who have never had MVTE, consenting to first-degree relatives being contacted to participate in the present study
  • Written consent from propositi and family members

Who cannot take part

  • First-degree relatives whose propositus received preventive antithrombotic medication during pregnancy or contraception
  • Family members of propositus who have had superficial or muscular venous thrombosis
  • Family members under 16 years of age
  • Vulnerable persons other than minors aged 16 to 18 (guardianship, curatorship)
  • No information can be obtained on first-degree relatives
  • Not affiliated to or not benefiting from a health insurance scheme

Other criteria

  • Eligibility criteria:
  • Propositi with objectively confirmed proximal deep vein thrombosis (i.e. ultrasonography) or pulmonary embolism (i.e. lung scanning) in women (18 to 50 years) while on hormonal exposure

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboprophylaxy during pregnancy. However, such practice is probably not accurate nor discriminent. Indeed, there are evidence that the impact of the familial history of VTE might be stronger than that of detectable inherited thrombophilia.

Read full original descriptionShow less

The "FIT-H" study is a cross-sectional study comparing the prevalence of previous venous thromboembolism in first-degree relatives of women (propositi) who had a first episode of venous thromboembolism in association with hormonal exposure with the prevalence of previous venous thromboembolism in first-degree relatives of women who did not have venous thromboembolism during a similar hormonal exposure.

The primary objective is to determine the association between the presence or the absence of VTE in young women during hormonal exposure and the presence or the absence of a previous episode of VTE in their first-degree relatives. Secondary objective is to determine the impact of associated inherited thrombophilia on the risk of VTE in first-degree relatives.

The 2 groups in the trial

  • Case group

    The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.

  • Control group

    The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Risk of Venous Thromboembolism in First Degree Relatives of Women With or Without Venous Thromboembolism During Hormonal Exposure
Plain-language title
Blood clots in relatives of women with hormone-related venous thromboembolismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
16 June 2026